EUVIMEDEUVIMED entdecken
Crossref

Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?

Benedikt Hoeh, Felix K H Chun, Philipp Mandel

Chinese Clinical Oncology · 2024

DOI: 10.21037/cco-23-66 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chinese Clinical Oncology, 2024. Verfasst von Benedikt Hoeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantPyrazolesMaleHumansDocetaxelAndrogen AntagonistsAndrogensStandard of CareAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

ARASENSPEACE-1Triplet therapydoublet therapymetastatic hormone-sensitive prostate cancer (mHSPC)

Substanzen

DocetaxelAndrogen AntagonistsdarolutamideAndrogensPyrazoles

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.

Zitieren

APA

Hoeh, B., Chun, F. K. H., & Mandel, P. (2024). Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?. Chinese Clinical Oncology. https://doi.org/10.21037/cco-23-66

Vancouver

Hoeh B, Chun FKH, Mandel P. Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?. Chinese Clinical Oncology. 2024. doi:10.21037/cco-23-66

BibTeX
@article{Hoeh2024,
  author = {Hoeh, Benedikt and Chun, Felix K H and Mandel, Philipp},
  title = {Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?},
  journal = {Chinese Clinical Oncology},
  year = {2024},
  doi = {10.21037/cco-23-66}
}
Kostenlos starten →